GTC Biotherapeutics and OVATION Pharmaceuticals Close Agreement to Market and Develop ATryn(R) in the U.S.
Thursday August 14, 8:00 am ET
FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced the closing of its previously announced collaboration agreement with OVATION Pharmaceuticals, Inc. (“OVATION”) to develop and market ATryn® in the United States. ATryn® is GTC’s recombinant form of human antithrombin, a plasma protein with anticoagulant and anti-inflammatory properties. The agreement includes $257 million in potential payments to GTC for meeting clinical, regulatory, and sales milestones, including a $3 million payment from OVATION to GTC at the closing, $2 million in payments anticipated for regulatory milestones in 2008, and up to an additional $4 million in milestone payments through a successful approval of ATryn® in 2009 for the hereditary antithrombin deficiency, or HD, indication.
ADVERTISEMENT
ATryn® has already been granted both Orphan Drug designation and Fast Track status for HD by the U.S. Food and Drug Administration. GTC has requested Priority Review as part of the Biologics License Application, or BLA, submitted for licensure of ATryn® in preventing deep vein thrombosis in HD patients undergoing high risk surgical procedures and in childbirth. Assuming GTC’s request for Priority Review is granted, a decision on market approval by the FDA could be reached in the first quarter of 2009.